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Abstract:  Mycobacterium tuberculosis FabH, an essential enzyme in the mycolic   
acid biosynthetic pathway, is an attractive target for novel anti-tubercolosis agents. 
Structure-based design and synthesis of 1-(4-carboxybutyl)-4-(4-(substituted benzyloxy) 
phenyl)-1H-pyrrole-2-carboxylic acid derivatives 7a–h, a subset of eight potential FabH 
inhibitors, is described in this paper. The Vilsmeier-Haack reaction was employed as a key 
step. The structures of all the newly synthesized compounds were identified by IR,   
1H-NMR, 
13C-NMR, ESI-MS and HRMS. The alamarBlue™ microassay was employed to 
evaluate the compounds 7a–h against Mycobacterium tuberculosis H 37Rv. The results 
demonstrate that the compound 7d possesses good in vitro antimycobacterial activity against 
Mycobacterium tuberculosis H37Rv (Minimum Inhibitory Concentration value [MIC],   
12.5 µg/mL).These compounds may prove useful in the discovery and development of new 
anti-tuberculosis drugs. 
Keywords: tuberculosis; Mycobacterium tuberculosis FabH; structure based design; 
synthesis; alamarBlue™ microassay 
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1. Introduction 
According to data of the World Health Organization [1], Tuberculosis (TB) caused by 
Mycobacterium tuberculosis, is considered to be the most chronic communicable disease in the World 
especially in Asia and Africa. This situation was made worse by the emergence of multi drug resistant 
TB (MDR-TB) and the increasing number of HIV-positive TB cases [2]. Worldwide, TB accounts for 
approximately one-fourth of HIV-related deaths and is the leading cause of death in HIV-infected adults 
in developing countries [3–5], thus an urgent need exists for the development of new antimycobacterial 
agents with a unique mechanism of action. 
The mycobacterial cell wall, which is composed of mycolic acids (α-alkyl-β-hydroxy long chain 
fatty acids) is known to be important for the growth, survival, and pathogenicity of mycobacteria. 
Mycobacteria contain both type I (FAS I) and type II (FAS II) fatty acid biosynthetic pathways. FAS is 
a single multifunctional polypeptide that catalyzes all the reactions in the elongation pathway [6,7]. On 
the other hand, FAS II system is catalyzed by a series of small, soluble proteins that are each encoded 
by a discrete gene existing as separate proteins. Mycobacterium tuberculosis β-ketoacyl-acyl carrier 
protein synthase III (mtFabH) is a key condensing enzyme responsible for initiation of FAS II fatty 
acid biosynthetic pathway, and has emerged as an attractive new target for novel anti-tuberculosis 
agents in recent years. Structure-based design, synthesis of novel inhibitors of mtFabH was reported in 
this paper. 
2. Results and Discussion 
We studied all available information about mtFabH, including known FabH inhibitors, substrates, 
and the active site topology from available mtFabH crystal structures. According to the structures of 
the anti-mycobacterial compounds FAS20013, SB418011 and the predicted binding mode of the other 
known anti-tuberculosis agents [8–11], we designed a novel scaffold structurs. This structure was 
predicted to possess improved binding affinity, as shown in Figure 1. 
Figure 1. Predicted binding model of compound 7d in the active site tunnel of mtFabH. 
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First, a substituted benzyloxy group is required to fill a complementary hydrophobic region at the 
top of the active site tunnel. Second, the presence of halogen or alkyl substituent is needed in order to 
form an ionic interaction with the arginine residues (Arg249) at the top of the active site tunnel. Third, 
the substituted group acidic groups are required to fill the bottom of the active site tunnel, and 
expected to form direct interaction (such as hydrogen bond) with the catalytic residues (Cys112, 
His244, Ser276 and Asn274). The scaffold structure itself merely serves as a carrier on which these 
three binding elements are arranged. 
We chose mtFabH (PDB ID: 1HZP) [12] as the docking target, and used an automated molecular 
docking and database screening program DOCK 4.0 [13,14]. A virtual compound library containing 
7,560 diverse combinations of substituted benzyloxy and various lengths of fatty acid chains were 
constructed using Project Library 2.0, a multifunctional combinatorial library construction program [15]. 
The constructed library was then virtually screened to identify the potential candidate compounds that 
display favorable binding to the protein active site. The top 500 high free energy score of derivatives 
from computer screening were carefully investigated. After taking drug-like properties and synthetic 
accessibility into account, a subset of eight candidate compounds were chosen to be synthesized first. 
The synthesis of a series of potential mtFabH inhibitors are reported in this paper.  
Scheme 1. Synthesis of 4-(4-(substituted benzyloxy)phenyl)-1-(3-carboxybutyl)-1H-
pyrrole-2-carboxylic acid. 
 
Reagents and conditions: (i) DMF POCl3, 90 °C, 5.5 h; (ii) H2O, NaClO4, r.t., 4 h, 76%; (iii) MeOH, 
Na, methyl 2-aminoacetate hydrochloride reflux, 24 h, 76%; (iv) C2H5OOC(CH2)3Br,  n-Bu4NBr, 
K2CO3, acetone, 50 °C, 4 h, 82%; (v) PhNMe2, AlCl3, CH2Cl2, r.t., 0.5 h, 79%; (vi) RBr, n-Bu4NBr, 
K2CO3, acetone, 50 °C, 2–4 h, 84%–96%; (vii) NaOH, CH3OH, H2O, 25 °C, 30 min, 67%–94%. Molecules 2012, 17 4773 
 
 
Scheme 1. Cont. 
Entry R  Product Yield  (%)   
1  4-chloro  7a  67 
2  4-methyl  7b  90 
3  4-methoxy  7c  66 
4  3,5-difluoro  7d  94 
5  3-methyl  7e  89 
6  3-chloro  7f  88 
7  2,6-dichloro  7g  97 
8  3,4-dimethyl  7h  75 
As shown in Scheme 1, commercially available 4-benzyloxybenzoic acid (1) was used to prepare 
the vinamidinium salts 2 by the standard Vilsmeier-Haack reaction [16]. When compound 1 was 
treated with a large excess of Vilsmeier reagent, followed by the addition of sodium perchlorate 
solution, the 4-benzyloxyphenyl vinamidinium salt was isolated in 76% yield [17]. The cyclization of 
4-benzyloxyphenyl vinamidinum salt 2 with methyl 2-aminoacetate hydrochloride in refluxing 
methanol in the present of sodium methoxide afforded pyrrole-2-carboxylate 3 in 76% yield. Ethyl  
4-bromobutanoate with n-Bu4NBr and anhydrous K2CO3 were successively added to a stirred   
solution of 3 in acetone to afford pyrrole-2-carboxylate 4. Compound 4 was treated with AlC13 and  
N,N-dimethylaniline in CH2Cl2 to obtain pyrrole-2-carboxylate 5 in 79% yield. To a DMF solution 
were added compound 5, substituted benzyl halides and anhydrous K2CO3 to generate the 
corresponding pyrrole-2-carboxylates 6a–h. Compounds 6a–h were hydrolyzed using sodium 
hydroxide in a mixture of methanol and water to give compounds 7a–h in 60%–90% yield. 
We determined the antimycobacterial activity of the compounds 7a–h utilizing a reference strain 
sensitive to Mycobacterium tuberculosis first-line antibiotics (H37Rv), obtaining important activity, 
with a MIC value 12.5 μg/mL. All of the compounds obtained were established unequivocally through 
analysis of their spectroscopic data. We found no report in the literature on the antituberculosis 
evaluation of these compounds. The results of their activity are presented in Table 1. 
Table 1. Antimycobacterial activity (Minimum inhibitory concentration [MIC] μg/mL) of 
the compounds 7a–h. 
Comp. No.  R  MIC 
7a  4-chloro  >25 
>25 
>25 
12.5 
>25 
25 
25 
>25 
0.046 
7b  4-methyl 
7c  4-methoxy 
7d  3,5-difluoro 
7e  3-methyl 
7f  3-chloro 
7g  2,6-dichloro 
7h  3,4-dimethyl 
INH  
Compounds  7a,  7b,  7e and 7h have alkyl substituted benzyloxy, which did not demonstrate 
antituberculosis activity in this study. With regard to the antituberculous activity of the compounds 7f Molecules 2012, 17 4774 
 
 
and 7g, they demonstrated little such activity against the assayed strains (H37Rv), with MIC values 
ranging between 12.5 and 25 μg/mL. The compound 7d’s MIC value was found to be 12.5 μg/mL. 
Further evaluation such as the activity of anti XDR-Mtb strains is still in progress. 
3. Experimental 
3.1. Materials and Reagents 
All the reagents for synthesis were commercially available and either used without further 
purification or purified by standard methods prior to use. Melting points were determined using a  
RY-1 apparatus, and the thermometer was uncorrected. 
1H-NMR and 
13C-NMR spectra were measured 
using an ARX400 multinuclear Fourier transform (FT)-NMR spectrometer (Bruker). Mass spectra 
were obtained from Micromass ZabSpec 1000 and API3000 instruments. 
3.2. Synthesis of Starting Compounds 2–5 
4-Benzyloxyphenyl vinamidinium salt (2). The Vilsmeier-Haack reagent was prepared by slow addition 
of anhydrous DMF (44 g, 0.6 mol) to phosphorus oxychloride (18.4 g, 0.12 mol) with stirring at 0 °C 
under a nitrogen atmosphere. The reaction mixture was left at room temperature for 1 h and then  
4-benzyloxyphenylacetic acid (1, 96.8 g, 0.4 mol) was added and the reaction mixture was stirred for 
4.5 h at 90 °C. An aqueous solution (100 mL) of sodium perchlorate (6.2 g, 0.044 mol) was added and 
the resulting mixture was stirred for 1 h at room temperature. The 4-benzyloxyphenyl vinamidinium salt 
was isolated in 76% yield. 
4-(4-(Benzyloxy)phenyl)-1H-pyrrole-2-carboxylate ( 3). A dry, three-necked, round-bottomed flask 
(500 mL) was equipped with a reflux condenser and magnetic stirrer. Under a nitrogen atmosphere 
sodium (1.75 g, 0.08 mol) was charged to the flask and then dry methanol (200 mL) was added and the 
resulting mixture was allowed to react for several minutes while stirring. Methyl 2-aminoacetate 
hydrochloride (6.4 g, 0.046 mol) was added and then compound 2 (12.5 g, 0.031 mol) was added. The 
resulting mixture was refluxed for 24 h, and the solvent was removed in vacuo. To the residue was 
added water (100 mL) and then the aqueous solution was extracted by EtOAc (3 × 50 mL). Combined 
organic phase was dried with anhydrous sodium sulfate for 2 h. After filtering out sodium sulfate, the 
solvent was removed in vacuo. The crude product was crystallized twice with the mixture of EtOAc 
and hexane to give 7.2 g (76% yield) of pure compound 3 as a white solid which had the following 
properties: Mp 207–208 °C; Rf = 0.2 (hexanes-EtOAc, 3:1). IR (KBr): 3,282, 3,117, 1,678, 1,617, 
1,581, 1,570, 1,523, 1,477, 1,465, 1,440, 1,382, 1,297, 1,254, 1,192, 1,180, 1,053, 1,041, 1,026, 994, 
926, 809, 769, 728, 692 cm
–1. 
1H-NMR (DMSO-d6): δ = 11.98 (s, 1H), 7.521–7.543 (d, 2H, J = 8.5 Hz), 
7.306–7.460 (m, 6H), 7.101–7.111 (t, 1H, J = 4 Hz), 6.958–6.980 (d, 2H, J = 8.8 Hz), 5.11 (s, 2H), 
3.78 (s, 3H). 
13C-NMR (DMSO-d6): δ = 160.8, 156.6, 137.2, 128.4, 127.7, 127.6, 127.4, 125.9, 124.9, 
122.4, 120.5, 115.0, 111.6, 69.1, 51.0. ESI-MS m/z = 308.1 [M+H]
+. 
Methyl 1-(4-ethoxy-4-oxobutyl)-4-(4-(benzyloxy)phenyl)-1H-pyrrole-2-carboxylate (4). Ethyl 4-bromo-
butanoate (4.73 g, 24.4 mol) with n-Bu4NBr (10.5 g, 32.6 mmol) and anhydrous K2CO3 (4.5 g,   
32.6 mmol) were successively added to a stirred solution of intermediate 3 (5 g, 16.3 mmol) in acetone Molecules 2012, 17 4775 
 
 
(100 mL). The mixture was stirred at 50 °C for 4 h and then the aqueous layer was separated and was 
acidified with 1 N HCl to pH 4. The aqueous layer was extracted with EtOAc (3 × 50 mL). The 
combined organic layer was dried (Na2SO4), filtered, and concentrated under reduced pressure, the 
remaining residue was purified by column chromatography [silica gel, hexane-EtOAc (v/v) = 10:1] to 
afford 5.6 g (13.3 mmol, 82% yield) of intermediate 4 as a white solid which had the following 
properties: Mp 70–71 °C; Rf = 0.3 (hexanes-EtOAc, 8:1). IR (KBr): 3,442, 2,955, 1,728, 1,698, 1,618, 
1,567, 1,513, 1,449, 1,392, 1,277, 1,258, 1,192, 1,102, 1,069, 1,041, 1,025, 829, 800, 759, 735,   
697 cm
–1. 
1H-NMR (DMSO-d6): δ = 7.326–7.537 (m, 8H), 7.172–7.177 (d, 1H, J = 2 Hz), 6.976–6.997 
(d, 2H, J = 8.4 Hz), 5.107 (s, 2H), 4.302–4.336 (t, 2H, J = 13.6 Hz), 3.989–4.042 (q, 2H, J = 21.2 Hz), 
3.758 (s, 3H), 2.235–2.272 (t, 2H, J = 14.8 Hz), 1.959–1.995 (m, 2H), 1.132–1.168 (t, 3H, J = 14.4 Hz). 
13C-NMR (DMSO-d6): δ = 172.1, 160.6, 156.7, 137.2, 128.4, 127.7, 127.6, 126.8, 126.1, 125.8, 122.9, 
121.4, 115.1, 114.3, 69.2, 59.9, 51.0, 47.5, 30.5, 26.2, 14.0. ESI-MS m/z = 422.2 [M+H]
+. HRMS-FAB: 
m/z [M+H]
+ calcd for C25H28N1O5: 422.19620; found: 422.19754. 
Methyl 1-(4-ethoxy-4-oxobutyl)-4-(4-(benzyloxy)phenyl)-1H-pyrrole-2-carboxylate ( 5). To a mixture 
of compound 4 (5.6 g, 13.2 mmol) and N,N-dimethylaniline (12.7 mL, 100 mmol) in anhydrous 
CH2Cl2 (30 mL) was added powdered AlC13 (5.2 g, 39.6 mmol) at room temperature. The reaction 
mixture was stirred for 30 min and then quenched by addition of 1N HCl. The aqueous layer was 
separated and extracted with EtOAc (3 × 50 mL). The combined organic phase was successively 
washed with 5% NaHCO3 solution and brine, and then dried over anhydrous Na2SO4 for 1 h. After 
filtered out Na2SO4, the organic solvent was removed under reduced pressure. The remaining residue 
was purified by column chromatography [silica gel, hexanes-EtOAc (v/v) = 4:1] to afford compound 5 
3.48 g (10.5 mmol) as a colorless, oily liquid in 79% yield which had the following properties: Rf = 0.3 
(hexanes-EtOAc, 3:1). 
1H-NMR (DMSO-d6): δ = 9.110 (s, 1H), 7.347–7.483 (m, 3H), 7.094–7.099 (d, 
1H, J = 2 Hz), 6.711–6.740 (m, 2H), 4.312–4.346 (t, 2H, J = 13.6 Hz), 3.997–4.050 (q, 2H, J = 21.2 Hz), 
3.768 (s, 3H), 2.245–2.282 (t, 2H, J = 14.8 Hz), 1.967–2.002 (m, 2H), 1.121–1.177 (t, 3H, J = 14.4 Hz). 
13C-NMR (DMSO-d6): δ = 172.1, 160.6, 155.8, 125.8, 125.0, 123.4, 121.2, 115.5, 114.1, 59.9, 51.0, 
47.5 30.5, 26.3, 14.0. ESI-MS m/z = 322.1 [M+H]
+. 
3.3. General Procedure for the Synthesis of Compounds 6a–h 
General Procedure 
Methyl 1-(4-ethoxy-4-oxobutyl)-4-(4-(substituted-benzyloxy)phenyl)-1H-pyrrole-2-carboxylate. To a 
solution of intermediate 5 (1 mmol, 0.331 g) and n-Bu4NBr (0.64 g, 2 mmol) in acetone (20 mL) were 
added anhydrous K2CO3 (0.28 g, 2 mmol) and substituted benzyl halides (1.5 mmol). After stirring for 
4 h at room temperature, to the reaction mixture 1 N HCl (10 mL) was added. The organic portion was 
extracted with EtOAc (3 × 20 mL). The combined organic phase was dried for a while and then 
Na2SO4 was filtered off and the filtrate was concentrated in vacuo. The residue was purified by column 
chromatography [silica gel, gradient elution with hexane-EtOAc (v/v) = 1:10–1:5] to give the 
corresponding product. Molecules 2012, 17 4776 
 
 
Methyl 1-(4-ethoxy-4-oxobutyl)-4-(4-(4-chlorobenzyloxy)phenyl)-1H-pyrrole-2-carboxylate  (6a). 
Colorless, oily liquid; yield: 513 mg (93%); Rf = 0.3 (hexanes-EtOAc, 8:1). 
1H-NMR (DMSO-d6):  
δ = 7.403–7.558 (m, 6H), 7.176–7.226 (m, 2H), 6.972–7.009 (m, 2H), 5.111–5.152 (t, 2H, J = 16.4 Hz), 
4.306–4.339 (t, 2H, J = 13.2 Hz), 3.988–4.042 (q, 2H, J = 21.6 Hz), 3.761 (s, 3H), 2.238–2.276 (t, 2H, 
J = 15.2 Hz), 1.962–2.014 (m, 2H), 1.132–1.168 (t, 3H, J = 14.4 Hz). 
13C-NMR (DMSO-d6):  
δ = 172.5, 161.0, 156.8, 136.6, 132.7, 130.7, 129.8, 127.6, 126.4, 126.1, 121.7, 115.4, 114.7, 110.8, 
68.5, 60.2, 51.3, 47.9, 30.9, 26.6, 14.3. ESI-MS m/z = 456.2 [M+H]
+. 
Methyl 1-(4-ethoxy-4-oxobutyl)-4-(4-(4-methylbenzyloxy)phenyl)-1H-pyrrole-2-carboxylate ( 6b). 
Colorless, oily liquid; yield: 501 mg (95%); Rf = 0.3 (hexanes-EtOAc, 6:1). 
1H-NMR (DMSO-d6):  
δ = 7.476–7.498 (m, 3H), 7.319–7.339 (d, 2H, J = 8 Hz), 7.170–7.201 (m, 3H), 6.957–6.980 (d, 2H,  
J = 9.2 Hz), 5.050 (s, 2H), 4.302–4.336 (t, 2H, J = 13.6 Hz), 3.990–4.043 (q, 2H, J = 21.2 Hz), 3.758 
(s, 3H), 2.235–2.303 (m, 5H), 1.961–1.996 (m, 2H), 1.133–1.168 (t, 3H, J = 14 Hz).
13C-NMR 
(DMSO-d6): δ = 172.1, 160.1, 156.8, 136.9, 134.1, 128.9, 127.7, 126.7, 125.1, 122.9, 121.4, 115.1, 
114.3, 69.1, 59.5, 51.0, 47.5, 30.5, 26.3, 20.7, 14.0. ESI-MS m/z = 436.2 [M+H]
+. 
Methyl 1-(4-ethoxy-4-oxobutyl)-4-(4-(4-methoxybenzyloxy)phenyl)-1H-pyrrole-2-carboxylate  (6c). 
Colorless, oily liquid; yield: 525 mg (96%); Rf = 0.3 (hexanes-EtOAc, 5:1). 
1H-NMR (DMSO-d6):  
δ = 7.479–7.530 (m, 3H), 7.364–7.386 (d, 2H, J = 8.8 Hz), 7.173–7.239 (m, 1H), 6.867–6.981 (m, 4H), 
5.015 (s, 2H), 4.304–4.338 (t, 2H, J = 13.6 Hz), 3.991–4.044 (q, 2H, J = 21.2 Hz), 3.731–3.759 (m, 6H), 
2.237–2.274 (t, 2H, J = 14.8 Hz), 1.963–2.016 (m, 2H), 1.134–1.169 (t, 3H, J = 14.4 Hz). 
13C-NMR 
(DMSO-d6): δ = 172.1, 160.5, 158.9, 156.8, 129.4, 127.9, 126.7, 126.1, 125.7, 122.9, 115.1, 114.3, 
113.8, 113.4, 68.9, 59.8, 55.0, 50.9, 47.6, 30.5, 26.2, 14.0. ESI-MS m/z = 452.2 [M+H]
+. 
Methyl 1-(4-ethoxy-4-oxobutyl)-4-(4-(3,5-difluorobenzyloxy)phenyl)-1H-pyrrole-2-carboxylate ( 6d). 
Colorless, oily liquid; yield: 519 mg (94%); Rf = 0.3 (hexanes-EtOAc, 6:1). 
1H-NMR (DMSO-d6):  
δ = 7.514–7.542 (m, 3H), 7.189–7.201 (m, 4H), 6.994–7.016 (d, 2H, J = 8.8 Hz), 5.149 (s, 2H),  
4.318–4.352 (t, 2H, J = 13.6 Hz), 3.773 (s, 3H), 2.249–2.287 (t, 2H, J = 15.2 Hz), 1.978–2.032  
(m, 2H), 1.141–1.177 (t, 3H, J = 14.4 Hz). 
13C-NMR (DMSO-d6): δ = 172.1, 163.6, 160.6, 156.3, 
142.0, 127.2, 126.1, 125.8, 122.8, 121.5, 115.1, 114.3, 110.2, 103.0, 67.8, 59.8, 50.9, 47.6, 30.5, 26.2, 
14.0. ESI-MS m/z = 458.2 [M+H]
+. 
Methyl 1-(4-ethoxy-4-oxobutyl)-4-(4-(3-methylbenzyloxy)phenyl)-1H-pyrrole-2-carboxylate ( 6e). 
Colorless, oily liquid; yield: 489 mg (93%); Rf = 0.3 (hexanes-EtOAc, 6:1). 
1H-NMR (DMSO-d6):  
δ = 7.488–7.529 (m, 3H), 7.126–7.291 (m, 5H), 6.972–6.994 (m, 2H), 5.054 (s, 2H), 4.307–4.342 (t, 
2H, J = 14 Hz), 3.993–4.047 (q, 2H, J = 21.6 Hz), 3.762 (s, 3H), 2.239–2.317 (m, 5H), 1.986–2.004 
(m, 2H), 1.135–1.171 (t, 3H, J = 14.4 Hz). 
13C-NMR (DMSO-d6): δ = 172.1, 160.6, 137.5, 137.1, 
128.3, 126.8, 126.1, 125.8, 124.7, 122.9, 121.4, 115.0, 114.3, 69.2, 59.9, 50.9, 47.5, 30.5, 26.2, 20.9, 
14.0. ESI-MS m/z = 436.2 [M+H]
+. 
Methyl 1-(4-ethoxy-4-oxobutyl)-4-(4-(3-chlorobenzyloxy)phenyl)-1H-pyrrole-2-carboxylate ( 6f). 
Colorless, oily liquid; yield: 402 mg (84%); Rf = 0.3 (hexanes-EtOAc, 8:1). 
1H-NMR (DMSO-d6):  
δ = 7.420–7.552 (m, 6H), 7.173–7.201 (m, 2H), 6.987–7.009 (m, 2H), 5.107–5.149 (t, 2H,   Molecules 2012, 17 4777 
 
 
J = 16.8 Hz), 4.311–4.345 (t, 2H, J = 13.6 Hz), 3.993–4.046 (q, 2H, J = 21.2 Hz), 3.766 (s, 3H), 
2.243–2.280 (t, 2H, J = 14.8 Hz), 1.988–2.005 (m, 2H), 1.135–1.171 (t, 3H, J = 14.4 Hz). 
13C-NMR 
(DMSO-d6): δ = 72.5, 160.9, 156.8, 140.1, 133.4, 130.6, 129.7, 128.7, 128.0, 127.5, 126.1, 123.2, 
121.7, 115.4, 114.6, 110.7, 68.5, 60.2, 51.3, 47.9, 30.9, 26.6, 14.3. ESI-MS m/z = 456.2 [M+H]
+. 
Methyl 1-(4-ethoxy-4-oxobutyl)-4-(4-(2,6-dichlorobenzyloxy)phenyl)-1H-pyrrole-2-carboxylate  (6g). 
Colorless, oily liquid; yield: 493 mg (95%); Rf = 0.3 (hexanes-EtOAc, 10:1). 
1H-NMR (DMSO-d6):  
δ = 7.451–7.580 (m, 6H), 7.196–7.201 (d, 1H, J = 2 Hz), 7.032–7.054 (d, 2H, J = 8.8 Hz), 5.232 (s, 
2H), 4.313–4.347 (t, 2H, J = 13.6 Hz), 3.995–4.048 (q, 2H, J = 21.2 Hz), 3.766 (s, 3H), 2.245–2.282 (t, 
2H,  J = 14.8 Hz), 1.970–2.005 (m, 2H), 1.139–1.174 (t, 3H, J = 14 Hz). 
13C-NMR (DMSO-d6):  
δ = 172.5, 160.9, 158.9, 141.7, 133.8, 129.7, 129.2, 128.0, 127.3, 122.5, 115.3, 114.9, 111.1, 60.2, 
51.3, 47.5 30.9, 26.3, 14.0. ESI-MS m/z = 490.1 [M+H]
+. 
Methyl 1-(4-ethoxy-4-oxobutyl)-4-(4-(3, 4-dimethylbenzyloxy)phenyl)-1H-pyrrole-2-carboxylate ( 6h). 
Colorless, oily liquid; yield: 449 mg (95%); Rf = 0.3 (hexanes-EtOAc, 6:1). 
1H-NMR (DMSO-d6):  
δ = 7.483–7.527 (m, 3H), 7.067–7.262 (m, 4H), 6.957–7.020 (m, 2H), 5.003–5.062 (d, 2H, J = 23.6 Hz), 
4.311–4.339 (t, 2H, J = 11.2 Hz), 4.009–4.030 (m, 2H), 3.762–3.801 (m, 3H), 2.203–2.266 (m, 8H), 
1.968–2.003 (m, 2H), 1.134–1.169 (m, 3H). 
13C-NMR (DMSO-d6): δ = 172.5, 160.9, 157.2, 136.5, 
136.0, 130.6, 134.7, 129.9, 129.7, 129.2, 127.0, 126.4, 126.1, 125.5, 123.3, 121.7, 115.3, 114.6, 68.8, 
60.2, 51.3, 47.9, 30.9, 26.6, 19.7, 19.4, 14.3. ESI-MS m/z = 450.2 [M+H]
+. 
3.4. General Procedure for the Synthesis of Compounds 7a–h 
General Procedure 
1-(4-carboxybutyl)-4-(4-(substituted benzyloxy)phenyl)-1H-pyrrole-2-carboxylic acid. To a stirred 
solution of intermediate 6a–h in MeOH (50 mL) was added 1 N NaOH (10 mL) at 25 °C. The mixture 
was stirred at the same temperature for 30 min. The aqueous layer was separated and was acidified 
with 1N HCl to pH-4. The aqueous layer was extracted with EtOAc (3 × 50 mL). The combined 
organic layer was dried (Na2SO4), filtered, and crystallized twice with EtOAc to give pure 7a–h. 
1-(3-Carboxypropyl)-4-(4-(4-chlorobenzyloxy)phenyl)-1H-pyrrole-2-carboxylic acid (7a). White solid; 
yield: 313 mg (67%); Mp: 163–164 °C; IR (KBr): 2,958, 1,690, 1,597, 1,512, 1,489, 1,454, 1,434, 
1,376, 1,291, 1,178, 1,107, 1,062, 931, 827, 802 cm
–1; 
1H-NMR (DMSO-d6): δ = 12.193 (s, 2H), 
7.464–7.514 (m, 6H), 7.123–7.198 (m, 2H), 6.965–7.001 (m, 2H), 5.109 (s, 2H), 4.290–4.324 (t, 2H,  
J = 13.6 Hz), 2.147–2.185 (t, 2H, J = 15.2 Hz), 1.922–1.958 (m, 2H); 
13C-NMR (DMSO-d6):  
δ = 172.5, 160.9, 156.8, 140.1, 133.4, 130.6, 129.7, 128.7, 128.0, 127.5, 126.1, 123.2, 121.7, 115.4, 
114.6, 110.7, 68.5, 60.2, 51.3, 47.9, 30.9, 26.6, 14.3; ESI-MS: m/z = 416.5 [M+H]
+; HRMS-FAB: m/z 
[M+H]
+ calcd for C22H21Cl1N1O5: 414.11028; found: 414.10991. 
1-(3-Carboxypropyl)-4-(4-(4-methylbenzyloxy)phenyl)-1H-pyrrole-2-carboxylic acid (7b). White 
solid; yield: 409 mg (90%); Mp: 186–187 °C; IR (KBr): 2,936, 1,702, 1,616, 1,568, 1,486, 1,291, 
1,266, 1,255, 1,203, 1,178, 815, 802 cm
–1; 
1H-NMR (DMSO-d6): δ = 12.174 (s, 2H), 7.107–7.482 (m, 
8H), 6.951–6.973 (d, 2H, J = 8.8 Hz), 5.049 (s, 1H), 4.287–4.321 (t, 2H, J = 13.6 Hz), 2.304 (s, 3H), Molecules 2012, 17 4778 
 
 
2.145–2.183 (t, 2H, J = 15.2 Hz), 1.902–1.975 (m, 2H); 
13C-NMR (DMSO-d6): δ = 173.8, 161.7, 
156.6, 137.0, 134.1, 128.9, 127.7, 127.1, 125.7, 125.5, 122.5, 122.5, 115.1, 114.3, 69.1, 47.5, 30.7, 
26.4, 20.7; ESI-MS m/z = 394.4 [M+H]
+; HRMS-FAB: m/z [M+H]
+ calcd for C23H24N1O5: 394.16490; 
found: 394.16551. 
1-(3-Carboxypropyl)-4-(4-(4-methoxybenzyloxy)phenyl)-1H-pyrrole-2-carboxylic acid (7c). White 
solid; yield: 313 mg (66%); Mp: 177–178 °C; IR (KBr): 3,412, 1,749, 1,731, 1,690, 1,612, 1,567, 
1,487, 1,402, 1,385, 1,305, 1,284, 1,177, 1,149, 1,094, 832, 810 cm
–1; 
1H-NMR (DMSO-d6):  
δ = 12.182 (s, 2H), 7.464–7.486 (m, 3H), 7.367–7.388 (d, 2H, J = 8.4 Hz), 7.109–7.114 (d, 1H,  
J = 2.0 Hz), 6.933–6.974 (m, 4H), 5.013 (s, 1H), 4.287–4.322 (t, 2H, J = 14.0 Hz), 3.754 (s, 3H), 
2.145–2.183 (t, 2H, J = 15.2 Hz), 1.902–1.956 (m, 2H); 
13C-NMR (DMSO-d6): δ = 173.8, 161.7, 
158.9, 156.7, 129.4, 129.0, 127.0, 125.7, 125.5, 122.6, 122.5, 115.1, 114.2, 113.8, 68.9, 55.1, 47.5, 
30.7, 26.4; ESI-MS m/z = 410.2 [M+H]
+; HRMS-FAB: m/z [M+H]
+ calcd for C23H24N1O6: 410.15981; 
found: 410.16113. 
1-(3-Carboxypropyl)-4-(4-(3,5-difluorobenzyloxy)phenyl)-1H-pyrrole-2-carboxylic acid ( 7d). White 
solid; yield: 445 mg (94%); Mp: 178–179 °C; IR (KBr): 3,113, 1,732, 1,689, 1,666, 1,615, 1,567, 
1,513, 1,451, 1,431, 1,404, 1,383, 1,307, 1,272, 1,255, 1,247, 1,201, 1,094, 1,057, 1,017, 833, 801, 
778, 699 cm
–1; 
1H-NMR (DMSO-d6): δ = 12.203 (s, 2H), 7.488–7.516 (m, 3H), 7.127–7.198 (m, 4H), 
6.980–7.002 (d, 2H, J = 8.8 Hz), 5.151 (s, 2H), 4.292–4.326 (t, 2H, J = 13.6 Hz), 2.148–2.168 (t, 2H,  
J = 15.2 Hz), 1.924–1.960 (m, 2H); 
13C-NMR (DMSO-d6): δ = 173.8, 161.7, 156.1, 127.5, 125.8, 
125.6, 122.5, 122.4, 115.1, 114.3, 110.4, 110.4, 110.2, 103.1, 67.8, 47.5, 30.7, 26.5; ESI-MS   
m/z = 416.3 [M+H]
+; HRMS-FAB: m/z [M+H]
+ calcd for C22H19F2N1O5: 416.13041; found: 416.13095. 
1-(3-Carboxypropyl)-4-(4-(3-methylbenzyloxy)phenyl)-1H-pyrrole-2-carboxylic acid (7e). White solid; 
yield: 381 mg (89%); Mp: 181–182 °C; IR (KBr): 3,113, 2,912, 1,732, 1,689, 1,666, 1,615, 1,567, 
1,513, 1,451, 1,431, 1,404, 1,383, 1,307, 1,272, 1,255, 1,247, 1,201, 1,180, 1,094, 1,057, 1,017, 833, 
801, 778 cm
–1; 
1H-NMR (DMSO-d6): δ = 12.217 (s, 2H), 7.474–7.497 (m, 3H), 7.224–7.296 (m, 3H), 
7.119–7.149 (m, 2H), 6.964–6.986 (d, 2H, J = 8.8 Hz), 5.060 (s, 2H), 4.290–4.323 (t, 2H, J = 13.2 Hz), 
2.321 (s, 3H), 2.147–2.184 (t, 2H, J = 14.8 Hz), 1.903–1.975 (m, 2H); 
13C-NMR (DMSO-d6):  
δ = 173.8, 161.7, 156.7, 137.5, 137.1, 128.4, 128.3, 128.2, 127.1, 125.7, 125.5, 124.7, 122.5, 122.4, 
115.0, 114.2, 113.8, 69.2, 47.5, 30.7, 26.4, 21.0; ESI-MS m/z = 394.4 [M+H]
+; HRMS-FAB: m/z 
[M+H]
+ calcd for C23H24N1O5: 394.16490; found: 394.16600. 
1-(3-Carboxypropyl)-4-(4-(3-chlorobenzyloxy)phenyl)-1H-pyrrole-2-carboxylic acid (7f). White solid; 
yield: 322 mg (88%); Mp: 173–174 °C; IR (KBr): 2,972, 1,716, 1,668, 1,599, 1,567, 1,513, 1,449, 
1,436, 1,379, 1,287, 1,245, 1,215, 1,102, 1,055, 932, 830, 810 cm
−1; 
1H-NMR (DMSO-d6): δ = 12.217 
(s, 2H), 7.424–7.519 (m, 6H), 7.127–7.178 (m, 2H), 6.977–7.000 (m, 2H), 5.110 (s, 2H), 4.291–4.324 
(t, 2H, J = 13.2 Hz), 2.148–2.186 (t, 2H, J = 15.2 Hz), 1.923–1.976 (m, 2H); 
13C-NMR (DMSO-d6):  
δ = 174.4, 162.3, 156.9, 140.4, 133.6, 130.9, 130.0, 129.0, 128.2, 127.8, 126.6, 126.3, 126.1, 115.7, 
114.9, 111.0, 68.8, 48.1, 31.2, 27.0; ESI-MS m/z = 414.6 [M+H]
+; HRMS-FAB: m/z [M+H]
+ calcd for 
C22H21Cl1N1O5: 414.11028; found: 414.10996. Molecules 2012, 17 4779 
 
 
1-(3-Carboxypropyl)-4-(4-(2,6-dichlorobenzyloxy)phenyl)-1H-pyrrole-2-carboxylic acid ( 7g). White 
solid; yield: 394 mg (87%); Mp: 208–209 °C; IR (KBr): 3,433, 2,956, 1,706, 1,657, 1,564, 1,510, 
1,453, 1,437, 1,383, 1,302, 1,288, 1,263, 1,237, 1,208, 1,190, 1,175, 1,106, 1,055, 1,016, 830,   
791 cm
–1; 
1H-NMR (DMSO-d6):  δ = 12.232 (s, 2H), 7.456–7.586 (m, 6H), 7.142–7.148 (d, 1H,   
J = 2.4 Hz), 7.030–7.052 (d, 2H, J = 8.8 Hz), 5.230 (s, 2H), 4.300–4.334 (t, 2H, J = 13.6 Hz),  
2.157–2.195 (t, 2H, J = 15.2 Hz), 1.913–1.991 (m, 2H); 
13C-NMR (DMSO-d6): δ = 173.8, 161.7, 
156.8, 136.0, 131.8, 131.5, 128.8, 127.6, 125.8, 125.6, 122.5, 122.4, 115.0, 114.3, 65.0, 40.1, 30.7, 
26.4; ESI-MS m/z = 448.3 [M+H]
+; HRMS-FAB: m/z [M+H]
+ calcd for C22H20Cl2N1O5: 448.07130; 
found: 448.07186. 
1-(3-Carboxypropyl)-4-(4-(3,4-dimethylbenzyloxy)phenyl)-1H-pyrrole-2-carboxylic acid ( 7h). White 
solid; yield: 306 mg (75%); Mp: 157–158 °C; IR (KBr): 2,947, 1,716, 1,668, 1,567, 1,512, 1,451, 
1,436, 1,364, 1,286, 1,263, 1,178, 1,103, 1,053, 931, 829, 811 cm
–1; 
1H-NMR (DMSO-d6): δ = 12.228 
(s, 2H), 7.465–7.508 (m, 3H), 7.069–7.262 (m, 4H), 6.948–7.012 (m, 2H), 5.013 (s, 2H), 4.293–4.321 
(t, 2H, J = 11.2 Hz), 2.212–2.271 (m, 6H), 2.146–2.166 (t, 2H, J = 8 Hz), 1.922–1.974 (m, 2H);  
13C-NMR (DMSO-d6): δ = 173.8, 161.7, 156.7, 135.7, 134.8, 134.5, 129.4, 128.9, 127.1, 125.7, 125.5, 
125.2, 122.5, 122.5, 115.1, 115.0, 114.3, 68.5, 47.5, 30.7, 26.5, 19.4, 19.1; ESI-MS m/z = 408.4 
[M+H]
+; HRMS-FAB: m/z [M+H]
+ calcd for C24H26N1O5: 408.18055; found: 408.18128. 
3.5. Antimycobacterial Activity Determination by Fluorometric Microplate Alamar Blue Assay 
The methodology was fully described by Collins and Luna-Herrera [18,19], but some modifications 
were made in the present study. The test was performed in 96-well sterile microplates (Falcon3072; 
Becton Dickinson, Lincoln Park, NJ, USA). A solution of isoniazid (Sigma cooperation) was prepared 
in sterile water at a concentration of 5 mg/mL; Pure compounds 7a–h were dissolved in DMSO at a 
concentration of 5 mg/mL. The highest concentration wells received 7H9 broth (199 μL).Then the 
solution of compound (1 μL) was added to the well. The H37Rv was grown in 7H9 broth (Difco, 
Detroit, MI, USA) supplemented with 10% (vol/vol) OADC (oleic acid, albumin, dextrose, catalase; 
Difco), and 0.05% (vol/vol) Tween 80 (Sigma) at 37 °C in one or two weeks until their turbidity 
reached McFarland 1 (10
7 CFU/mL). Simultaneously a 1:20 diluted control was prepared from the 
bacterial suspension, which represented the growth of 10% of the bacterial population tested.   
Final testing concentrations are 0.2–0.0125 μg/mL for the isoniazid and from 0.2–25 μg/mL for   
pure compounds.  
Next, serial two-fold dilutions were prepared and an aliquot of the bacterial suspension (100 μL) 
was added to these wells. The plates were incubated at 37 °C after 7 days of incubation, one control 
was developed with 20 μL of 10× alamarBlue™ and 5% Tween80 50 μL solution. The plates were 
reincubated at 37 °C for 24 h. After this incubation, if the well turned pink, all wells received 
alamarBlue™ solution and were incubated for an additional 24 h. Fluorescence was measured in a 
plate fluorometer at a 530-nm excitation wavelength and a 590-nm emission wavelength and Relative 
fluorescence units (RFU) were recorded. Minimum inhibitory concentration (MIC) was defined as the 
lowest extract of pure compounds concentration that presented RFU values lower than those presented Molecules 2012, 17 4780 
 
 
by the 10% growth control. There was always a correlation between fluorometric and visual observation, 
i.e., pink wells presented high RFU values. The assay results are summarized in Table 1. 
4. Conclusions 
The present study supports the fact that 1-(4-carboxybutyl)-4-(4-(substituted-benzyloxy)phenyl)-
1H-pyrrole-2-carboxylic acid derivatives  display good activity against resistant Mycobacterium 
tuberculosis. The compound 7d’s MIC value was found 12.5 μg/mL. Further evaluationg such as the 
activity of anti XDR-Mtb strains is still in progress. These products may be useful for the development 
of anti-tuberculosis drugs. 
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